<p>我最喜欢关注的股票之一就是低价股。当这些年轻的新兴公司发布消息时，它们的股价可能会有巨大波动。当然，如果消息是积极的，这些波动通常会向上，而负面消息通常会导致股价下跌。</p>
<p>虽然短期波动可能令人兴奋，但早期购买正确的低价股并长期持有可能会带来显著收益。当然，考虑风险也很重要。大多数低价股最终会失败。因此，在投资这些小公司时，不要投入无法承受损失的资金很重要。尽管如此，如果你有 1000 美元想要投资于低价股，你应该考虑以下选择。</p>
<p><strong>要点</strong>:</p>
<ul>
<li>低价股存在风险，但可能带来显著收益。</li>
<li>Allogene Therapeutics 有几项正在进行的临床和临床前项目，可能会带来未来的催化剂。</li>
<li>Yalla Group 是新兴经济体中强大的社交网络和游戏公司。</li>
<li>如果分析师的预测准确，金山云可能会飙升。</li>
<li>如果你正在寻找现在购买低成本股票并在未来获得显著利润的机会，请停止搜索。查看我们的免费新报告 “发现下一个英伟达” 以了解两只可能增长 10 倍或更多的低成本股票！</li>
</ul>
<h2>如果试验顺利，Allogene Therapeutics 可能会获得强劲收益</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/03/imageForEntry3-HMC.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/03/imageForEntry3-HMC.jpg"/></p>
<p>Allogene Therapeutics（纳斯达克：ALLO）是一家临床阶段的生物技术公司，专注于使用独特变种的 CAR-T 细胞作为治疗血液癌症、实体肿瘤癌症和自身免疫性疾病的潜在治疗方法。令人印象深刻的是，该公司针对的癌症类型是一些最难治疗的癌症形式。积极的临床数据和最终的商业化可能为巨大的盈利奠定基础。前提是一切在临床中顺利进行。</p>
<p>该公司在临床中非常活跃。目前正在进行三项 2 期临床试验、四项 1 期临床试验和几项临床前项目。当然，任何一项试验或临床前项目的积极数据都可能推动股价飙升。而且由于有这么多正在进行的试验和项目，数据发布可能随时发生。</p>
<p>值得注意的是，分析师对该股票持有绝大多数积极看法。17 位分析师发表了意见，其中 8 位给予买入评级。四位分析师给予 Allogene Therapeutics 超越市场表现的评级，而五位给予持有评级。该股票的中位价格目标目前为 9 美元，对于目前交易价格远低于 3 美元的股票来说，这个价格不错。</p>
<h2>Yalla Group 是一个引人注目的新兴投资</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/07/GettyImages-631611026-scaled.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/07/GettyImages-631611026-scaled.jpg"/></p>
<p>当我投资于低价股时，我喜欢扩大搜索范围，寻找新兴经济体中的机会。毕竟，随着这些经济体的崛起，参与公司的经济机会也会增加。这就是 Yalla Group（纽约证券交易所：YALA）的价值所在。</p>
<p>Yalla Group 是中东和北非地区最大的社交网络和游戏公司之一。该公司在第四季度拥有 3620 万月活跃用户，显示出其快速增长。事实上，月活跃用户同比增长超过 13%，而且没有迹象表明这种增长会很快放缓。</p>
<p>重要的是，Yalla Group 有两类用户——付费用户和免费服务用户。当然，免费用户比付费用户更容易增加，但 Yalla Group 两者都在增长。事实上，第四季度付费用户同比增长超过 6%。</p>
<p>那么分析师们怎么看？</p>
<p>目前只有两位分析师对该股票发表意见；一位给予买入评级，另一位给予持有评级。中位价格目标目前为 5.70 美元，代表着未来可能有显著增长的潜力。</p>
<h2>分析师预计金山云将会飙升</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry6-82h.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry6-82h.jpg"/></p>
<p>金山云（纳斯达克：KC）是一家云计算服务提供商。该公司提供 CDN、人工智能工具和研究、云服务以及服务器负载平衡等服务。</p>
<p>该公司一直非常成功。它连续一段时间实现了营收和盈利的增长。在最近的一个季度，营收增长超过 3%，而每股摊薄收益增长超过 30%。</p>
<p>尽管这令人印象深刻，但也许最引人注目的统计数据是分析师们对未来极端增长的预期。目前有 10 位分析师对金山云股票发表意见。其中五位分析师给予买入评级，一位给予超越市场表现的评级，四位给予持有评级。中位价格目标目前为 26.26 美元，为未来的强劲增长奠定了基础。</p>
<h2><strong>想提前退休？从这里开始（赞助商）</strong></h2>
<p>想比原计划提前几年退休？或者你已经准备好退休，但希望有人帮助你审视财务状况？</p>
<p>现在你可以免费与你所在地区的最多 3 位财务专家交谈。只需点击这里，你就可以开始与可以帮助你制定提前退休计划的财务专家匹配。最棒的部分是什么？你可以免费与他们进行第一次对话。</p>
<p>点击这里，与最多 3 位乐于帮助你做出财务决策的财务专家匹配。</p>
<p>本文发布在 24/7 Wall St.上，标题为《用 1000 美元购买的 3 只热门低价股》。</p>

金山云

雅乐科技

<p>这篇文章讨论了三只有潜力的低价股：Allogene Therapeutics（纳斯达克股票代码：ALLO）、挚文集团（纽约证券交易所股票代码：YALA）和金山云（纳斯达克股票代码：KC）。Allogene Therapeutics 是一家专注于先进癌症治疗的临床阶段生物技术公司，正在进行多项试验，并获得分析师积极的展望。挚文集团是一家在中东和北非地区快速增长的社交网络和游戏公司，展示出强劲的用户增长。金山云是一家云服务提供商，展现出持续增长的营收和强劲的盈利增长。低价股可能带来显著收益，但也伴随着较高的风险</p>

<p>Penny stocks are some of my favorite stocks to watch. When these young budding companies release news, their stock prices can make tremendous moves. Of course, if the news is positive, those moves will generally be upward, and downward movement typically follows negative news.</p>
<div class="lb-trans"><p>我最喜欢关注的股票之一就是低价股。当这些年轻的新兴公司发布消息时，它们的股价可能会有巨大波动。当然，如果消息是积极的，这些波动通常会向上，而负面消息通常会导致股价下跌。</p>
</div><p>While short-term movements can be exciting, buying the right penny stocks early and holding them for the long run can lead to significant gains. Of course, it’s important to consider the risk too. Most penny stocks will ultimately fail. So it’s important not to invest any money you can’t afford to lose when investing in these small companies. Nonetheless, if you have $1,000 that you’d like to invest in penny stocks, you should consider diving into the following picks.</p>
<div class="lb-trans"><p>虽然短期波动可能令人兴奋，但早期购买正确的低价股并长期持有可能会带来显著收益。当然，考虑风险也很重要。大多数低价股最终会失败。因此，在投资这些小公司时，不要投入无法承受损失的资金很重要。尽管如此，如果你有 1000 美元想要投资于低价股，你应该考虑以下选择。</p>
</div><p><strong>Key Points</strong>:</p>
<ul>
<li>Penny stocks are risky but can produce significant gains.</li>
<li>Allogene Therapeutics has several ongoing clinical and preclinical programs that could lead to catalysts ahead.</li>
<li>Yalla Group is a strong social networking and gaming play in an emerging economy.</li>
<li>Kingsoft Cloud could skyrocket if analysts are correct.</li>
<li>If you’re looking for low-cost stocks to buy now and make significant profits later, stop your search. Check out our free, new Discover “The Next NVIDIA” report to learn about two low-cost stocks that could grow by 10x or more ahead!</li>
</ul>
<div class="lb-trans"><p><strong>要点</strong>:</p>
<ul>
<li>低价股存在风险，但可能带来显著收益。</li>
<li>Allogene Therapeutics 有几项正在进行的临床和临床前项目，可能会带来未来的催化剂。</li>
<li>Yalla Group 是新兴经济体中强大的社交网络和游戏公司。</li>
<li>如果分析师的预测准确，金山云可能会飙升。</li>
<li>如果你正在寻找现在购买低成本股票并在未来获得显著利润的机会，请停止搜索。查看我们的免费新报告 “发现下一个英伟达” 以了解两只可能增长 10 倍或更多的低成本股票！</li>
</ul>
</div><h2>Allogene Therapeutics Could See Strong Gains If Trials Go Well</h2>
<div class="lb-trans"><h2>如果试验顺利，Allogene Therapeutics 可能会获得强劲收益</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/03/imageForEntry3-HMC.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/03/imageForEntry3-HMC.jpg"/></p>
<p>Allogene Therapeutics (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on using unique variations of CAR-T cells as potential treatments for blood cancers, solid tumor cancers, and autoimmune diseases. Impressively, the types of cancer the company is targeting with its therapeutic candidates are some of the most difficult forms of cancer to treat. Positive clinical data and eventual commercialization could set the stage for tremendous profitability. That is if all goes well in the clinic.</p>
<div class="lb-trans"><p>Allogene Therapeutics（纳斯达克：ALLO）是一家临床阶段的生物技术公司，专注于使用独特变种的 CAR-T 细胞作为治疗血液癌症、实体肿瘤癌症和自身免疫性疾病的潜在治疗方法。令人印象深刻的是，该公司针对的癌症类型是一些最难治疗的癌症形式。积极的临床数据和最终的商业化可能为巨大的盈利奠定基础。前提是一切在临床中顺利进行。</p>
</div><p>The company is highly active in the clinic, too. It’s currently working on three Phase 2 clinical trials, four Phase 1 clinical trials, and a handful of preclinical programs. Of course, any positive data out of any of these trials or preclinical programs could send the stock screaming for the top. And with so many ongoing trials and programs, data releases can happen at any time.</p>
<div class="lb-trans"><p>该公司在临床中非常活跃。目前正在进行三项 2 期临床试验、四项 1 期临床试验和几项临床前项目。当然，任何一项试验或临床前项目的积极数据都可能推动股价飙升。而且由于有这么多正在进行的试验和项目，数据发布可能随时发生。</p>
</div><p>It’s also worth noting that analysts have an overwhelmingly positive opinion of the stock. 17 analysts have shared opinions, eight of whom rate the stock a Buy. Four analysts rate Allogene Therapeutics an Outperform, while five rate it a Hold. The median price target on the stock is currently $9 — not bad for a stock that’s trading at well under $3 per share.</p>
<div class="lb-trans"><p>值得注意的是，分析师对该股票持有绝大多数积极看法。17 位分析师发表了意见，其中 8 位给予买入评级。四位分析师给予 Allogene Therapeutics 超越市场表现的评级，而五位给予持有评级。该股票的中位价格目标目前为 9 美元，对于目前交易价格远低于 3 美元的股票来说，这个价格不错。</p>
</div><h2>Yalla Group Is a Compelling Emerging Play</h2>
<div class="lb-trans"><h2>Yalla Group 是一个引人注目的新兴投资</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/07/GettyImages-631611026-scaled.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2024/07/GettyImages-631611026-scaled.jpg"/></p>
<p>When I invest in penny stocks, I like to expand my search to find opportunities in emerging economies. After all, as those economies emerge, economic opportunities for the companies involved increase. That’s where Yalla Group (NYSE: YALA) comes in.</p>
<div class="lb-trans"><p>当我投资于低价股时，我喜欢扩大搜索范围，寻找新兴经济体中的机会。毕竟，随着这些经济体的崛起，参与公司的经济机会也会增加。这就是 Yalla Group（纽约证券交易所：YALA）的价值所在。</p>
</div><p>Yalla Group is one of the largest social networking and gaming companies in the Middle East and North Africa. The company’s 36.2 million monthly active users in the fourth quarter show that it is growing quickly. In fact, monthly active users were up over 13% year over year, and there’s no sign that this growth will slow anytime soon.</p>
<div class="lb-trans"><p>Yalla Group 是中东和北非地区最大的社交网络和游戏公司之一。该公司在第四季度拥有 3620 万月活跃用户，显示出其快速增长。事实上，月活跃用户同比增长超过 13%，而且没有迹象表明这种增长会很快放缓。</p>
</div><p>Importantly, Yalla Group has two sets of users — those who pay and those who access free services. Of course, free users are easier to increase than paid users, but Yalla Group is seeing growth in both. In fact, paid users were up over 6% in the fourth quarter.</p>
<div class="lb-trans"><p>重要的是，Yalla Group 有两类用户——付费用户和免费服务用户。当然，免费用户比付费用户更容易增加，但 Yalla Group 两者都在增长。事实上，第四季度付费用户同比增长超过 6%。</p>
</div><p>So what do the analysts think?</p>
<div class="lb-trans"><p>那么分析师们怎么看？</p>
</div><p>There are only two analysts currently weighing in on the stock; one rates it a Buy, and the other rates it a Hold. The median price target is currently $5.70, representing the potential for significant growth ahead.</p>
<div class="lb-trans"><p>目前只有两位分析师对该股票发表意见；一位给予买入评级，另一位给予持有评级。中位价格目标目前为 5.70 美元，代表着未来可能有显著增长的潜力。</p>
</div><h2>Analysts Expect Kingsoft Cloud to Skyrocket</h2>
<div class="lb-trans"><h2>分析师预计金山云将会飙升</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry6-82h.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2019/12/imageforentry6-82h.jpg"/></p>
<p>Kingsoft Cloud (Nasdaq: KC) is a cloud computing service provider. The company offers services like CDNs, artificial intelligence tools and research, cloud services, and server load balancing among others.</p>
<div class="lb-trans"><p>金山云（纳斯达克：KC）是一家云计算服务提供商。该公司提供 CDN、人工智能工具和研究、云服务以及服务器负载平衡等服务。</p>
</div><p>The company has been pretty successful. It has consistently produced growth in revenue and earnings for some time. In the most recent quarter, revenue was up over 3%, while diluted earnings per share were up over 30%.</p>
<div class="lb-trans"><p>该公司一直非常成功。它连续一段时间实现了营收和盈利的增长。在最近的一个季度，营收增长超过 3%，而每股摊薄收益增长超过 30%。</p>
</div><p>While that’s impressive, perhaps the most striking statistic about the stock is the fact that analysts expect such extreme growth ahead. There are currently 10 analysts weighing in on KC shares. Five of those analysts rate the stock a Buy, one rates it an Outperform, and four rate it a Hold. The median price target is currently $26.26, setting the stage for strong growth ahead.</p>
<div class="lb-trans"><p>尽管这令人印象深刻，但也许最引人注目的统计数据是分析师们对未来极端增长的预期。目前有 10 位分析师对金山云股票发表意见。其中五位分析师给予买入评级，一位给予超越市场表现的评级，四位给予持有评级。中位价格目标目前为 26.26 美元，为未来的强劲增长奠定了基础。</p>
</div><h2><strong>Want to Retire Early? Start Here (Sponsor)</strong></h2>
<div class="lb-trans"><h2><strong>想提前退休？从这里开始（赞助商）</strong></h2>
</div><p>Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?</p>
<div class="lb-trans"><p>想比原计划提前几年退休？或者你已经准备好退休，但希望有人帮助你审视财务状况？</p>
</div><p>Now you can speak with up to 3 financial experts in your area for <strong>FREE</strong>. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.</p>
<div class="lb-trans"><p>现在你可以免费与你所在地区的最多 3 位财务专家交谈。只需点击这里，你就可以开始与可以帮助你制定提前退休计划的财务专家匹配。最棒的部分是什么？你可以免费与他们进行第一次对话。</p>
</div><p>Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.</p>
<div class="lb-trans"><p>点击这里，与最多 3 位乐于帮助你做出财务决策的财务专家匹配。</p>
</div><p>The post 3 Hot Penny Stocks to Buy With $1000 appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>本文发布在 24/7 Wall St.上，标题为《用 1000 美元购买的 3 只热门低价股》。</p>
</div>

用 1000 美元可以买的 3 只热门便士股票